EMA authorizes Phase 3 clinical trial for denovoSkin™
CUTISS has received authorization from the European Medicines Agency (EMA) to commence the Phase 3 clinical trial for our lead product denovoSkin™ in adult & adolescent severe burn patients.
Automated page speed optimizations for fast site performance